<DOC>
	<DOCNO>NCT00863811</DOCNO>
	<brief_summary>Elevated intraocular pressure still main risk factor development progression glaucoma . Several drug exist market may decrease IOP glaucomatous patient . However , patient reach target pressure despite multitherapy combination drug , therefore address surgical treatment . Forskolin natural compound receptor-independent adenyl-cyclase activator , increase intracellular cAMP . It show able decrease IOP topical application , mechanism use drug . Aim present study see whether oral administration food supplement contain forskolin ( KRONEK ) effect IOP POAG patient stable IOP obtain treatment either beta-blockers prostaglandin .</brief_summary>
	<brief_title>Effects Forskolin Intraocular Pressure Glaucomatous Patients Under Treatment With Either Beta-blockers Prostaglandins Eye Drops</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Colforsin</mesh_term>
	<criteria>Primary Open Angle Glaucoma associate ocular hypertension Target pressure achieve singleagent therapy ( betablockers prostaglandin ) Visual acuity &gt; 6/10 Miopy Hypermetropy &gt; 5D Concomitant ocular pathology Previous ocular surgery Known hypersensitivity component KRONEK tablet Concomitant participation trial Changes topic glaucoma therapy course study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>POAG</keyword>
	<keyword>IOP</keyword>
	<keyword>Forskolin</keyword>
	<keyword>beta-blockers</keyword>
	<keyword>prostaglandin</keyword>
</DOC>